The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
TB is arranging interviews with Sharetalk in the next couple of weeks but think this will be done after the next announcement/s due (Telemedicine launch for one). Re-connecting with Andrew Scott et al will make a huge difference for the company.
Another huge step for the company!
Telemedicine launch/partnership next!? Multiple other uses for IB tech news to come, SC sale, Gadolinium free project, IB stroke package, 510K FDA clearance on Liver Nodularity (soon).
Excited by the news to come & TB re-connecting with Sharetalk should get the buzz back!!
The sale of Stonechecker will increase company value but is a small part of the business - the IB software is where the huge potential is here & would expect to hear an update on broadening its use soon.
The news should be - Telemedicine launch/partnership within the next couple of weeks followed by Sharetalk interview/s which should ramp up the interest in the company, SC sale could be anytime, Gadolinium free project still on schedule, IB stroke package, 510K FDA clearance on Liver Nodularity & multiple usage of IB software again could be anytime & would expect an mention in the interviews .
The interview/s IQAI intend to do with Andrew Scott in the coming weeks should hopefully bring the markets attention back- The company are a year down the line with a lot more development & potential from the peak we saw at FDA approval for SC so i think now is the time for a sustained rise.
I expect the Telemedicine news to be announced in the next couple of weeks although the sale of SC could happen anytime & news on broader use of IB software is expected.
IQAI will be doing some Sharetalk interview/s in the next few weeks - got lots to share!
I think TB realises communication needs to be better & i think they will be a much more prominent noise on social media from here on.
Exciting time for IQAI!?
*should hear about the new partner soon to break into telemedicine
*2 interested parties for Stonechecker
*IB stroke product on schedule
*Expansion of use for IB software
*news on 510k FDA clearance for liver nodularity
*Gadolinium free project continues as planned
Great to see IQAI ramping up products and developments & branching into new areas for more revenue streams
News flow that is in the public domain.
New Partnership/Contract
Share buyback - approval now agreed 15% buyback option (circa 22 million shares)
Gadolinium free development - progressing a planned - patents pending
510(k) for Liver Nodularity application
Stonechecker sale
IB stroke package
Lets look at your statement 'rampers like you..,you have been doing the same since SP was near 9p and since it has lost 66% of its value...stop ramping..please'
I challenge you produce a single piece of evidence to justify this wildly inaccurate statement or an example of 'ramping' in my posts!?
If you feel you can write wildly inaccurate statements about people, in an attempt to undermine their position and risk reputational damage to that person I think you have to be accountable. I suggest you withdraw your statement to keep some integrity rather than me having to approach LSE.
I don't understand what point you are trying to make!? Do you want to discuss why the SP went to 15p and has fallen back to 3p!? or are we looking at where the company is now and has the potential to go based on the information in the public domain!?
'Positive Catalysts' - from info on recent RNS's & IQAI Twitter but please DYOR
New Partnership/Contract
Share buyback - approval request at AGM
Gadolinium free development - progressing a planned - patents pending
510(k) for Liver Nodularity application
Stonechecker sale
IB stroke package
IMO the fundamentals will move the SP higher as more pieces fall into place so it is not 'brave' for me to hold onto my shares when there is so much going on, it is purely logical. Obviously everyone has their own point of view and level of risk & should do what is best for them. The point of my post was to challenge your deliberate (& not subtle) use of the word 'brave' - for the purpose of balance you understand.
I think they will be asked about the pending partnership but they won't be able to say anymore until the contract has been signed & announcement made via RNS, which will be the same for the Stonechecker sale.
The fact a partnership was mentioned in a tweet may have been a slip but happy to be given a heads up & would expect an official announcement soon.
I think people who have researched the company know it is in excellent shape with plenty of exciting news to come this year! Happy to sit back and watch it unfold!
Pending partnership/contract - guessing we are waiting for it to be signed & RNS
Gadolinium free development - progressing a planned - also numerous patents pending (expected this year)
510(k) for Liver Nodularity application
Stonechecker sale
IB stroke package
Other!?
Difficult to predict the order/timelines for above but plenty of news to come & could be anytime
Short term i would like to see the SP back above 10p, but i am happy to sit back for a couple of months and see what developments are announced & may stay in longer term if I feel that a company sale is on the cards. Until that point there are plenty of stepping stones along the way to ratchet the SP up & until recently the most anticipated was the Stonechecker sale but I get the feeling there will be some exciting news ahead of that!
Claire, I think its easy to underestimate Trevor - although it is not his style to bang the drum to shareholders via social media about on-going developments & this can be frustrating as the SP is currently undervalued, i think he is making noises in the right places & is certainly well connected within the industry. The Stonechecker sale process will have also put IQAI on the map to a number of large companies who may wish to buy them outright & i'm sure they will be monitoring IQAIs latest developments.
Remember that Trevor is a circa 30% shareholder & he wants to add as much value to the company as he can before it sells & I think he is working extremely hard right now to tap into lucrative markets to achieve this.